## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average burden							
hours per response	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person *				2. Issuer Name and Ticker or Trading Symbol						5. Re	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)X Director					
Smith Edward F				Benitec Biopharma Inc. [BNTC]						_x_						
(Last) (First) (Middle) C/O BENITEC BIOPHARMA INC., 3940 TRUST WAY				3. Date of Earliest Transaction (Month/Day/Year) 12/09/2020							Officer (give	e title below)	Oth	er (specify below	7)	
(Street) HAYWARD, CA 94545				4. If Amendment, Date Original Filed(Month/Day/Year)						_X_ F	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person					
(City	y)	(State)	(Zip)	Table I - Non-Derivative Securities Acqu						quired,	ired, Disposed of, or Beneficially Owned					
1.Title of S (Instr. 3)	Security		2. Transaction Date (Month/Day/Year)	2A. Deeme Execution lany (Month/Da		Date, if (	. Transaction Code Instr. 8)		4. Securities Acq (A) or Disposed of (Instr. 3, 4 and 5)		Owned Follo Owned Follo Transaction (Instr. 3 and				Ownership Form: Direct (D)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
							Coc	de V	` '	) Pric	ee				Instr. 4)	
			Table II -					in this displa uired, Disp	form are n ys a curren oosed of, or l onvertible so	ot requi tly valid Beneficia	red to	respond control n	unless the	tion contain e form		. ,
	Conversion	3. Transaction Date (Month/Day/Year)  3A. Deemed Execution Date, if any (Month/Day/Year)	Code		Securities		6. Date Exercisable and Expiration Date (Month/Day/Year)		of U Sec	7. Title and Amount of Underlying Securities (Instr. 3 and 4)			9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s	Ownership Form of Derivative Security: Direct (D) or Indirect	(Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	e	Amount or Number of Shares		(Instr. 4)	(Instr. 4)	
Options (right to buy)	\$ 2.98	12/09/2020		A		23,601		(1)	12/09/20	13(1)	mmon tock	23,601	\$ 0	23,601	D	

#### **Reporting Owners**

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Smith Edward F C/O BENITEC BIOPHARMA INC. 3940 TRUST WAY HAYWARD, CA 94545	X					

#### **Signatures**

/s/ Edward Smith	12/11/2020
**Signature of Reporting Person	Date

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The stock options will vest in three substantially equal installments on the day prior to each of the Issuer???s next three annual stockholder meetings occurring immediately following the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.